LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the…
Hormone Replacement Strategies in Women at Moderate to High Risk for Breast Cancer – SABCS 2023
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast…
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at…
In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL),…
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023]
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Elranatamab for Black Patients with Relapsed Multiple Myeloma [ASH 2023]
Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone…
ERG: New Gene Linked to Blood Disorders and Hematologic Cancers [ASH 2023]
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology…
Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…